Analysts expect Capricor Therapeutics to report Q3 2026 revenue of $10.40 million and a loss per share of $0.61, while the stock trades around $9.02—well below the $30.25 average analyst price target.
The primary focus for this report is the upcoming FDA PDUFA date on November 22, 2026, for deramiocel, a potential first-in-class cell therapy for Duchenne muscular dystrophy (DMD).
Investors are looking for updates on the regulatory review following a recent extension to evaluate additional data from the Phase 3 HOPE-3 trial. Capricor recently reported a cash balance of $238 million, which supports its preparations for a potential commercial launch in 2026.